-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $175

Benzinga·02/13/2026 14:40:37
Listen to the news
Wells Fargo analyst Mohit Bansal maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $180 to $175.